4-(Phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4)

Journal of Medicinal Chemistry

Volumn 51, Issue 12, 2008, Pages 3507-3525

  Tsou, Hwei Ru ^a   Otteng, Mercy ^a   Tran, Tritin ^a,b   Floyd Jr , M Brawner ^a   Reich, Marvin ^a   Birnberg, Gary ^a   Kutterer, Kristina ^a   Ayral Kaloustian, Semiramis ^a   Ravi, Malini ^a   Nilakantan, Ramaswamy ^a   Grillo, Mary ^a   McGinnis, John P ^a   Rabindran, Sridhar K ^a,b  

^a WYETH RESEARCH   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (3 HYDROXYPHENYL) 4 [[[(4 PIPERIDIN 1 YLMETHYL)PHENYL]AMINO]METHYLENE]ISOQUINOLINE 1,3(2H,4H) DIONE; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 BROMO 4 [[(4 PIPERIDIN 1 YLMETHYL)PHENYL]AMINO]METHYLENEISOQUINOLINE 1,3(2H,4H) DIONE; 6 BROMO 4 [[[4 (4 METHYLPIPERAZIN 1 YL)PHENYL]AMINO]METHYLENE]ISOQUINOLINE 1,3(2H,4H) DIONE; ANILINE DERIVATIVE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; ROSCOVITINE; WAY 186084;

ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITOR INTERACTION; ENZYME REGULATION; HUMAN; HUMAN CELL; NEOPLASM; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 4; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; ISOQUINOLINES; MODELS, MOLECULAR; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 45749125689     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800072z     Document Type: Article

References (33)

1. Massague, J. G1 cell cycle and cancer. Nature 2004, 432, 298-306.
2. Shapiro, G. I. Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment. J. Clin. Oncol. 2006, 24 (11), 1770-1783.
3. Dyson, N. The regulation of E2F by pRB-family proteins. Gene Dev. 1998, 12, 2245-2262.
4. Hanahan, D.; Weiberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70.
5. Grillo, M.; Bott, M. J.; Khandke, N.; McGinnis, J. P.; Miranda, M.; Meyyappan, M.; Rosfjord, E. C.; Rabindran, S. K. Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res. Treat. 2006, 95, 185-194.
6. Malumbres, M.; Barbacid, M. Is Cyclin D1-CDK4 kinase a bona fide cancer target? Cancer Cell 2006, 9, 2-4.
7. Tetsu, O.; McCormick, F. Proliferation of cancer cells despite cdk2 inhibition. Cancer Cell 2003, 3, 233-245.
8. Ortega, S.; Prieto, I.; Odajima, J. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. 2003, 35, 25-31.
9. (a) Berthet, C.; Aleem, E.; Coppola, V. Cdk2 knockout mice are viable. Curr. Biol. 2003, 13, 1775-1785.
10. Sanderwicz, A. M. Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol Ther. 2003, 2, S84-S95.
11. Fry, D. W.; Harvey, P. J.; Keller, P. R. Specific inhibition of cyclin-dependent kinase 4/6 by PD0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 2004, 3, 1427-1438.
12. McClue, S. J.; Blake, D.; Clarke, R. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 2002, 102, 463-468.
13. Misra, R. N.; Xiao, H. Y.; Kim, K. S. N-(cycloalkylamino)acyl-2- aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1- dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly effficacious and selective antitumor agent. J. Med. Chem. 2004, 47, 1719-1728.
14. Grell, W.; Walter, R.; Heckel, A.; Himmelsbach, F.; Wittneben, H.; van Meel, J.; Redemann, N.; Haigh, R. Preparation of 3-(α- heteroarylaminobenzylidene)-2-indolinones as cyclin dependent kinase inhibitors. German Patent DE 19815020 A1, October 7, 1999.
15. Crockett, G. C.; Swanson, B. J.; Anderson, D. R.; Koch, T. H. A preferred method for imide preparation. Synth. Commun. 1981, 11, 447-454.
16. Wolfbeis, O. S.; Trummer, I.; Knierzinger, A. 2-Substituierte pyrano[2,3-c]isochinolin-3,6-dione und merocyaninfarbstoffe aus homophthalsaureimiden. Liebigs Ann. Chem. 1981, 811-818.
17. (a) Perez, D.; Bures, G.; Guitian, E.; Castedo, L. Synthesis of antitumor lycorines by intramolecular Diels-Alder reaction. J. Org. Chem. 1996, 61, 1650-1654.
18. Hauser, F. M.; Rhee, R. Carboxylation of dilithium ortho-toluates. Synthesis 1977, 245-246.
19. Young, S. D.; Wiggins, J. M.; Huff, J. R. 3,4-Dihydrobenz[f] isoquinoline and 3,4-dihydrobenz[g]isoquinoline. J. Org. Chem. 1988, 53, 1114-1116.
20. Shtutman, M.; Zhurinsky, J.; Simcha, I.; Albanese, C.; D'Amico, M.; Pestell, R.; Ben-Ze'ev, A. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 5522-5527.
21. Tam, S. W.; Theodoras, A. M.; Shay, J. W.; Draetta, G. F.; Pagano, M. Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with cdk4 is required for cyclin D1 function in G1 progression. Oncogene 1994, 9, 2663-2674.
22. Ikuta, M.; Kamata, K.; Fukasawa, K.; Honma, T.; Machida, T.; Hirai, H.; Suzuki-Takahashi, I.; Hayama, T.; Nishimura, S. Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein. J. Biol. Chem. 2001, 276, 27548-27554.
23. GLIDE; Schrodinger Software: Portland, OR; www.schrodinger.com.
24. (a) McInnes, C.; Wang, S.; Anderson, S.; O'Boyle, J.; Jackson, W.; Kontopidis, G.; Meades, C.; Mezna, M.; Thomas, M.; Wood, G.; Lane, D. P.; Fischer, P. M. Structural Determinants of CDK4 Inhibition and Design of Selective ATP Competitive Inhibitors. Chem. Biol. 2004, 11, 525-534.
25. (b) Honma, T.; Hayashi, K.; Aoyama, T.; Hashimoto, N.; Machida, T.; Fukasawa, K.; Iwama, T.; Ikeura, C.; Iduta, M.; Suzuki-Takahashi, I.; Iwasawa, Y.; Hayama, T.; Nishimura, S.; Morishima, H. Structure-Based Generation of a New Class of Potent cdk4 Inhibitors: New de Novo Design Strategy and Library Design. J. Med. Chem. 2001, 44, 4615-4627.
26. (c) Aubry, C.; Wilson, A. J.; Jenkins, P. R.; Mahale, S.; Chaudhuri, B.; Marechal, J.; Sutcliffe, M. J. Design, synthesis and biological activity of new CDK4-specific inhibitors based on fascaplysin. Org. Biomol. Chem. 2006, 4, 787-801.
27. Park, H.; Yeom, M. S.; Lee, S. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: Comparative molecular dynamics simulation studies of CDK2 and CDK4. ChemBioChem. 2004, 5, 1662-1672.
28. Pratt, D. J.; Bentley, J.; Jewsbury, F.; Boyle, T.; Endicott, J. A.; Noble, M. E. M. Dissecting the Determinants of Cyclin-Dependent Kinase 2 and Cyclin-Dependent Kinase 4 Inhibitor Selectivity. J. Med. Chem. 2006, 49, 5470-5477.
29. SYBYL, version 7.2; Tripos, Inc.: St. Louis, MO.
30. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput. Aided Mol. Des. 1997, 11, 425-445.
31. Jorgensen, W. L.; Maxwell, D. S.; Triado-Rives, J. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids. J. Am. Chem. Soc. 1996, 118 (45), 11225-11236.
32. Quallich, G. J.; Makowski, T. W.; SandersA. F.; Urban, F. J.; Vazquez, E. Synthesis of 1,2,3,4-Tetrahydroisoquinolines Containing Electron-Withdrawing Groups. J. Org. Chem. 1998, 63, 4116-4119.
33. Hurst, D. T.; Christophides, J. The synthesis of some 2-(substituted) 5-nitropyrimidines. Heterocycles 1977, 6 (12), 1999-2004.